The Effectiveness of Antiarrhythmic Drugs for Cardiac Arrhythmias in Patients with Proliferative Diseases during Polychemotherapy

Cardiac arrhythmias are a significant concern in patients with proliferative diseases undergoing polychemotherapy, as they can lead to severe complications and negatively impact treatment outcomes. This study evaluates the effectiveness of various antiarrhythmic drugs in managing arrhythmias in this patient population. A cohort of 150 patients diagnosed with hematological malignancies who experienced arrhythmias during chemotherapy was analyzed. Patients were treated with a range of antiarrhythmic agents, including beta-blockers, calcium channel blockers, and class I and III antiarrhythmics. The primary endpoints were the resolution of arrhythmias, recurrence rates, and overall cardiac function, assessed through electrocardiograms and echocardiography. Results indicated that 75% of patients experienced resolution of arrhythmias with antiarrhythmic treatment, while 25% had recurrent episodes during follow-up. Additionally, the use of beta-blockers was associated with improved cardiac function and a significant reduction in arrhythmia-related complications. This study emphasizes the importance of timely recognition and management of arrhythmias in patients undergoing polychemotherapy, as effective antiarrhythmic therapy can enhance patient safety and treatment efficacy.